A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to download ...

The CGM market is an exciting, fast-growing, multibillion-dollar medtech sector, according to our new Medtech Market ...

Significant strides were made in expanding CGM access, with coverage now available for nearly 6 million type 2 non-insulin users in the U.S. This expansion represents about half of the type 2 ...

Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...

The world's largest online retailer got a lift from its booming cloud computing business on Friday, Oct. 31, 2025, while a soft sales outlook weighed on a medical device firm's stock.

Dexcom Inc. executives may have thought a $30 million beat ... following issues with its G7 sensor, which management said have been largely resolved.

DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...

After dealing with a deployment issue with glucose monitors earlier this year, interim CEO Jake Leach said improving customer ...

DexCom was named a Barron’s stock pick in July. After DexCom shifted its focus to the Type 2 population last year, Type 1 ...

DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margin improvement ahead.

Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...

Medical device company DexCom (NASDAQ:DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales ...